Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Glioblastoma 380Brain Neoplasms 376Glioma 232Gliosarcoma 147Astrocytoma 138Neuroblastoma 121Central Nervous System Neoplasms 118Oligodendroglioma 80Medulloblastoma 61Breast Neoplasms 52Neoplasms 51Melanoma 45Ependymoma 43Carcinoma, Non-Small-Cell Lung 42Recurrence 40Sarcoma 33Meningioma 33Rhabdomyosarcoma 32Neurofibromatosis 1 32Osteosarcoma 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 27Wilms Tumor 26Lung Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Sarcoma, Ewing 23Lymphoma 22Rhabdoid Tumor 20Hepatoblastoma 19Testicular Neoplasms 17

Interventions

fludarabine 1Leukapheresis 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cytokine Release Syndrome × CNS × Clear all
NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡